NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q4 and Full-Year 2024 Financial Results, Highlights FDA Clearance and Commercial Progress
HeartBeam (NASDAQ: BEAT), a medical technology company focused on advanced cardiac care, announced its financial and operational results for the fourth quarter and full-year 2024. The company achieved key milestones, including FDA 510(k) clearance for the HeartBeam System, the launch of an Early Access Program to refine its clinical workflow, and the submission of an FDA application for its 12-lead ECG synthesis software. HeartBeam also raised $11.5 million in gross proceeds from a public offering to support commercialization efforts. Financially, research and development expenses rose to $11.1 million in 2024 from $6.8 million in 2023, while net loss widened to…







